http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
혈액 투석환자에서 혈중 알루미늄 농도에 관한 임상적 고찰
서연석 ( Yun Seok Seo ),길효욱 ( Hyo Wook Gil ),양종오 ( Jong Oh Yang ),이은영 ( Eun Young Lee ),홍세용 ( Sae Yong Hong ) 대한신장학회 2007 Kidney Research and Clinical Practice Vol.26 No.4
Purpose : This study was performed to evaluate the aluminum level in hemodialysis patients and to find a correlation between aluminum level and bone specific alkaline phosphatase level. Methods : Eighty five randomly selected patients with end-stage renal disease, undergoing maintenance hemodialysis treatment over 1 year were studied. Serum aluminum and bone specific alkaline phosphatase concentration were measured. Low dose desferrioxamine test (5 mg/kg) was done. Results : The serum aluminum concentration before and after low dose desferrioxamine test were 4.21±2.13 μg/L and 8.89±4.48 μg/L (p<0.01) respectively. Bone-specific alkaline phosphates and parathyroid hormone concentration were 39.08±39.90 mg/dL and 98.27±112.92 pg/mL. The aluminum level after desferrioxamine test was correlated with duration of hemodialysis (r=0.238, p=0.03). Aluminum level was not correlated with bone specific alkaline phosphatase level. Conclusion : Aluminum level was lower than that of previous studies. Aluminum level was not increased in patients with low bone specific alkaline phosphatase. Thus, it seems that serum aluminum level is not a major problem in hemodialysis patients with lower turnover bone disease. However, confirm diagnosis of aluminum related bone disease in hemodialysis patients needs combined study of bone histology with a large number of cases.
심지예,서연석,양종오,이은영,홍세용,길효욱,Shim, Ji-Yae,Seo, Yun-Seok,Yang, Jong-Oh,Lee, Eun-Young,Hong, Sae-Yong,Gil, Hyo-Wook 대한임상독성학회 2006 대한임상독성학회지 Vol.4 No.2
Acute toxic methemoglobinemia is an infrequent complication of the use of various drugs. Severe methemoglobinemia is very often fatal. Methylene blue is an effective drug in the treatment of methemoglobinemia patients. However, failure to respond to methylene blue has been described in patients with sulfhemoglobinemia, chlorate poisoning, and glucose-6-phosphate dehydrogenase deficiency. It is even possible that hemolysis may occur due to methylene blue treatment itself. We encountered a case of a 71-year-old woman who developed methemoglobinemia caused by alprazolam intoxication. She presented with hemolytic anemia and did not respond to methylene blue. In spite of concerted N-acetylcysteine therapy, the hemolytic anemia became aggravated and the patient died eleven days after intoxication.
강현석 ( Hyun Seok Kang ),최혁순 ( Hyuk Soon Choi ),윤태정 ( Tae Jung Yun ),이광균 ( Kwang Gyun Lee ),서연석 ( Yeon Seok Seo ),연종은 ( Jong Eun Yeon ),변관수 ( Kwan Soo Byun ),엄순호 ( Soon Ho Um ),김창덕 ( Chang Duck Kim ),류호 대한간학회 2009 Clinical and Molecular Hepatology(대한간학회지) Vol.15 No.4
산괴불주머니라는 약초에 의한 급성 독성간염의 1예를 보고하고자 한다. 환자는 상기 약초를 다려 먹은 후 황달이 발생하여 입원하였으나 약초로 인한 간손상이라고는 생각하지 않아 병력 청취 시 말하지 않았고, 결국 원인 규명은 이루어지지 못한 채 간손상이 호전되어 퇴원하였다. 그러나 퇴원 후 약초 재복용으로 인해 간손상이 악화되면서 비로소 복용 사실을 언급하였고 약인성 독성간염으로 확진하게 되었다. 약인성 간손상에서 복용 약물의 인지가 늦어지면 진단이 늦어질 뿐 아니라 재발의 가능성이 높아지므로 약물 사용력에 대해 보다 세밀한 조사가 필요할 것으로 생각한다. Herbs are widely used as treatments for various symptoms. However, several herbs have been reported to be inducers of liver injury. We report herein a case of hepatotoxicity induced by Corydalis speciosa Max. A 37-year-old male complained of jaundice and mild abdominal discomfort. A thorough history was taken, and laboratory investigation, diagnostic imaging studies, and percutaneous liver biopsy sampling were conducted to determine the cause of liver injury. An accurate cause was not revealed. We administered supportive management for acute cholestatic hepatitis of unknown origin, after which his symptoms disappeared and serum aminotransferase levels decreased gradually to near normal levels. However, at 2 months after discharge, the symptoms and the elevation of aminotransferase levels recurred. At that time he told us that he had repeatedly but unintentionally eaten a herb called “Hwang-geun cho”(Corydalis speciosa Max.). Thus, we diagnosed his case as herbal hepatotoxicity. (Korean J Hepatol 2009;15:517-523)
간세포암 환자의 종양병기 평가에 대한 Up-to-Seven Score의 임상적 유용성
정창호 ( Chang Ho Jung ),서연석 ( Yeon Seok Seo ),이재민 ( Jae Min Lee ),윤석배 ( Seok Bae Yoon ),윤태정 ( Tae Jung Yun ),임선영 ( Sun Young Yim ),안형진 ( Hyonggin An ),엄순호 ( Soon Ho Um ),김창덕 ( Chang Duck Kim ),류호상 ( Ho 대한간암학회 2014 대한간암학회지 Vol.14 No.1
Background/Aims: Up-to-seven criteria was proven to be useful for predicting prognosis after liver transplantation in patients with hepatocellular carcinoma (HCC). The aim of this study was to evaluate that up-to-seven score could be useful method for prediction of prognosis in patients with HCC who did not undergo liver transplantation. Methods: Between January 2006 and December 2008, 216 HCC patients without vascular invasion, lymph node and distant metastasis were analyzed retrospectively. We investigated the prognostic impact of laboratory findings, clinical characteristics, modified UICC T stage, and up-to-seven score in HCC. The survival analyses were performed using Kaplan-Meier Results: Two-hundred sixteen patients with HCC were included. Age was 60.1±11.3 years and 74.5% were male. Chronic hepatitis B was the most common cause of liver disease (60.6%). T stage was T1, T2, and T3 in 36 (16.7%), 118 (54.6%), and 62 (28.7%) patients, respectively. Up-to-even score was 5.5±4.0 and it was <3 (UTS 1), ≥3 and ≤7 (UTS 2), and >7 (UTS 3) in 36 (16.7%), 133 (61.6%), and 47 (21.8%) patients, respectively. The 10 (8.5%) patients of T2 stage were classified into UTS 3 and 25 (40.3%) patients of T3 stage were classified into UTS 2. The prognosis was significantly different in patients with T2 or T3 according to their UTS. Multivariate analysis showed that Child-Pugh score and UTS were significantly associated Conclusions: Up-to-seven score was useful to predict prognosis and to evaluate tumor stage in patients without vascular invasion, lymph node and distant metastasis.
권오상,김윤홍,연종은,변관수,이창홍,서연석,김윤홍 대한간학회 1999 Clinical and Molecular Hepatology(대한간학회지) Vol.5 No.1
Background/Aims : Several randomized controlled studies have shown that responders who had treated with interferon alpha for chronic hepatitis B had better rate of sustained loss of HBeAg and HBV DNA than non-responders. These studies also showed that non-responders had higher rates of liver related complication and mortality. But there is very little data on how well sustained responders are and whether the responders eventually lose HBsAg in Korea. The aims of this study were to better define the long term remission of chronic hepatitis B induced by interferon alfa therapy and compare the clinical outcome among the interferon responders and non-responders in Korea. Methods : Sixty-eight patients with chronic hepatitis B who were treated with interferon alfa between 1987 and 1998 were followed up for serologic status (HBsAg, HBeAg, HBV DNA), biochemical tests and liver related complication or mortality. Results : Among 68 patients with chronic hepatitis B who were treated with interferon alfa, 28 (41%) responded to treatment with loss of HBeAg within 1 year of starting treatment. Up to 129 months (mean 58 months) after therapy, responders had higher rate of cumulative clearance of HBeAg at five years than non-responders (100% vs 35.1%, p$lt;0.05). Responders had maintained the normal serum ALT than nonresponders at five years (94% vs 55.6%, p$lt;0.05). Loss of HBsAg was not different between responders and non-responders (5% vs 4%, NS). The rates of liver related complication and mortality did not differ between both groups. Delayed clearance of HBeAg occured in twelve out of forty non-responders (30%). There were no differences in age, baseline ALT, histologic finding of liver biopsy, HBV DNA at the end of first year after study with IFN therapy between the non-responders with and without delayed clearance of HBeAg. Conclusion : Remission in chronic hepatitis B induced by alfa interferon maintained in long duration. But clinical outcomes such as liver related complication, mortality and the elimination of HBV infection have no differences between responders and non-responders. Further studies are needed for the role of interferon therapy in long-term clinical outcome for chronic hepatitis B. (Korean J Hepatol 1999;5:12-21)